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ABSTRACT
Immobilization is a form of disuse characterized by a loss of strength
andmuscle mass. Among themain features are decreased IGF-1/Akt
signalling and increased ubiquitin-proteasome pathway signalling,
which induce greater myosin heavy chain degradation. Activation of
the classical renin-angiotensin system (RAS) causes deleterious
effects in skeletal muscle, including muscle wasting. In contrast,
angiotensin-(1-7) [Ang-(1-7)], a peptide of the non-classical RAS,
produces beneficial effects in skeletal muscle. However, the role of
Ang-(1-7) in skeletal muscle disuse atrophy and independent of
classical RAS activation has not been evaluated. Therefore, we
assessed the functions of Ang-(1-7) and the Mas receptor in disuse
muscle atrophy in vivo using unilateral cast immobilization of the hind
limb in male, 12-week-old wild-type (WT) and Mas-knockout (Mas
KO) mice for 1 and 14 days. Additionally, we evaluated the
participation of IGF-1/IGFR-1/Akt signalling and ubiquitin-
proteasome pathway expression on the effects of Ang-(1-7)
immobilization-induced muscle atrophy. Our results found that Ang-
(1-7) prevented decreased muscle strength and reduced myofiber
diameter, myosin heavy chain levels, and the induction of atrogin-1
and MuRF-1 expressions, all of which normally occur during
immobilization. Analyses indicated that Ang-(1-7) increases IGF-1/
IGFR-1/Akt pathway signalling through IGFR-1 and Akt
phosphorylation, and the concomitant activation of two downstream
targets of Akt, p70S6K and FoxO3. These anti-atrophic effects of
Ang-(1-7) were not observed in Mas KO mice, indicating crucial
participation of the Mas receptor. This report is the first to propose
anti-atrophic effects of Ang-(1-7) via the Mas receptor and the
participation of the IGF-1/IGFR-1/Akt/p70S6K/FoxO3 mechanism in
disuse skeletal muscle atrophy.
KEY WORDS: Disuse, Angiotensin-(1-7), Mas receptor, Skeletal
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INTRODUCTION
Disuse muscle atrophy is induced by low mechanical load (e.g. cast
immobilization) (Bodine, 2013). Morphological changes of disuse
include decreased muscle mass, cross-sectional muscle fiber area,
and strength (Bodine, 2013). Muscle mass maintenance depends
on protein synthesis and degradation equilibrium, which are
unbalanced during muscle wasting (Brooks and Myburgh, 2014).
In normal muscle, insulin-like growth factor-1 (IGF-1), via
IGFR-1, activates protein kinase B (Akt), resulting in p70S6 kinase
(p70S6K) phosphorylation and activation. During muscle atrophy,
activity of the IGF-1/Akt protein-synthesis pathway is decreased
(Latres et al., 2005; Clemmons, 2009; Frost and Lang, 2007).
Protein degradation increases during muscle wasting, primarily
affecting the skeletal muscle proteins myosin heavy chain (MHC)
and actin (Diffee et al., 2002; Meneses et al., 2015). Regarding this,
the ubiquitin-proteasome pathway (UPP) mediates most
myofibrillar protein degradation in skeletal muscle atrophy
(Lecker et al., 1999). The atrophy F-box protein (MAFbx; also
known as atrogin-1) and RING-finger protein-1 (MuRF-1), muscle-
specific E3 ligases, are upregulated in various skeletal muscle
wasting models (Foletta et al., 2011) and are gene targets of
Forkhead box, class O (FoxO) transcription factors (Sandri, 2008).
The renin-angiotensin system (RAS), which comprises classical
and non-classical axes, is a regulator of muscle mass (Cabello-
Verrugio et al., 2012a). The main classical RAS peptide is
angiotensin II (Ang II), which is associated with deleterious
effects in skeletal muscle (Cabello-Verrugio et al., 2015).
Angiotensin-(1-7) [Ang-(1-7)], the main non-classical RAS
peptide, exerts actions against Ang II via the G-protein-coupled
receptor Mas (Santos et al., 2003). These contrasting functions
prevent the insulin resistance, fibrosis, and autonomic dysfunction
associated with Duchenne muscular dystrophy and Ang-II-induced
skeletal muscle atrophy (Acuna et al., 2014; Cabello-Verrugio et al.,
2015; Riquelme et al., 2014). Ang-(1-7) minimizes Ang-II-induced
muscle wasting through UPP reduction by decreasing atrogin-1 and
MuRF-1 mRNA expressions, as well as by maintaining MHC
levels. Moreover, Ang-(1-7), via the Mas receptor, induces Akt
phosphorylation in skeletal muscle (Cisternas et al., 2015).
However, the role of Ang-(1-7), as a mechanism independent of
classical RAS activation, has not been evaluated in skeletal muscle
disuse atrophy. Therefore, the present study evaluated the effects of
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de Ciencias Quıḿicas y Biológicas, Facultad de Salud, Universidad
Bernardo O Higgins, Santiago 8370993, Chile. 10Departamento de
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immobilization model in mice (Krawiec et al., 2005; Morales et al.,
2015). Systemic Ang-(1-7) treatment prevented the atrophic effects
of disuse, restored muscle strength, and inhibited decreased muscle
diameter and mass in tibialis anterior (TA) and gastrocnemius (GA)
muscles of hind-limb-immobilized mice. All of these effects were
blunted in Mas-knockout (Mas KO) mice, suggesting Mas receptor
participation in Ang-(1-7) functions. Also through theMas receptor,
Ang-(1-7) decreased atrogin-1 and MuRF-1 expressions and
inhibited the drop in MHC levels normally associated with disuse.
Finally, in basal and disuse conditions, Ang-(1-7), through the Mas
receptor, increased IGF-1 expression and induced IGFR-1, Akt,
p70S6K and FoxO3 phosphorylation, suggesting also the
modulation of signalling pathways involved in protein synthesis.
RESULTS
Ang-(1-7) prevents the decreased muscle strength of disuse
atrophy through the Mas receptor
Decreased muscle strength is a main feature of cast-immobilization
skeletal muscle atrophy. After 14 days, the isometric strength of the
vehicle-treated immobilized TA muscle in wild-type (WT) mice
(WT/immobilized TA) was less than that of WT/non-immobilized
TA for all evaluated points on the frequency-strength curve
(Fig. 1A). Ang-(1-7) pre-treatment prevented this decrease in
isometric strength, with WT/immobilized TA showing values
similar to WT/non-immobilized TA. Interestingly, Ang-(1-7)- and
vehicle-treated WT/non-immobilized TA showed the same muscle
strength (Fig. 1A).
To evaluate Mas receptor participation in minimizing the effects
of disuse atrophy, the unilateral immobilization protocol was also
implemented in the hind limb ofMas KOmice. Isometric strength in
Mas KO/immobilized TA treated with a vehicle was similar to that
of WT/immobilized TA treated with a vehicle (Fig. 1A,B). In
contrast to WT mice, Ang-(1-7) pre-treatment did not improve
isometric strength in TA-immobilized Mas KO mice (Fig. 1B).
Maximal isometric force was also determined. Ang-(1-7) pre-
treatment prevented a decrease in maximal isometric force for WT/
immobilized TA (Fig. S1A). In contrast, Ang-(1-7) pre-treatment
did not prevent this decrease in Mas KO/immobilized TA
(Fig. S1B). Notably, the maximal isometric strengths of vehicle-
treated WT/− (WT/non-immobilized TA) and Mas KO/non-
immobilized TA were similar. In addition, the strength decreased
in the same proportion inWT/− andMas KO/immobilized TA (35%
and 38%, respectively).
These effects on isometric strength were also supported by
evaluations of the GA muscle (Fig. S1C,D). Specifically, the
immobilization-induced decrease in the tetanic isometric force of the
GAwas prevented by Ang-(1-7) pre-treatment via the Mas receptor.
These results indicate that Ang-(1-7), through the Mas receptor,
prevents the disuse loss of muscle strength in the TA and GA.
Ang-(1-7) inhibits the fiber diameter and muscle mass
reductions of disuse atrophy through the Mas receptor
The effects of Ang-(1-7) on muscle fiber diameters were evaluated
(Cisternas et al., 2015; Meneses et al., 2015). The minimal Feret
diameters of TA fibers were determined through wheat germ
agglutinin (WGA) staining (Fig. 2A), with quantifications showing
a shift in the curve towards smaller fibers in vehicle-treated WT/
immobilized TA (Fig. 2B, upper graph). This shift was reduced in
Ang-(1-7)-treated WT/immobilized TA (Fig. 2B, lower graph),
which showed fiber diameters similar to WT/non-immobilized TA.
However, Ang-(1-7) did not affect the Mas KO/immobilized TA,
which maintained a shift towards smaller fibers similar to vehicle-
treated Mas KO/immobilized TA (Fig. 2C,D). These results were
also supported by H&E stain in TA (Fig. S2A-D) and in the GA
muscle (Fig. S3A-D).
Skeletal muscle atrophy also significantly lowers muscle weight.
In this regard, Ang-(1-7) pre-treatment prevented weight loss by
38% in WT/immobilized TA as compared to the vehicle-treated
WT/immobilized TA (Fig. S4A). The effect of Ang-(1-7) pre-
treatment on muscle weight loss in Mas KO/immobilized TA was
null (Fig. S4B). Similar results were obtained in GA muscle from
WT (Fig. S4C) and Mas KO mice (Fig. S4D).
These results suggest that Ang-(1-7), through the Mas receptor,
decreases the anatomical impacts of disuse atrophy on skeletal
muscle.
Ang-(1-7) inhibits the lowered MHC levels and increased E3
ligaseexpressionsof disusemuscle atrophy through theMas
receptor
One of the main proteins affected by skeletal muscle atrophy is
MHC, the levels of which decrease through a mechanism involving
the UPP. Vehicle-treated WT/immobilized TA presented a 56.5%
decline in MHC levels compared to Ang-(1-7)-treated WT/
immobilized TA. The MHC levels of Ang-(1-7)-treated WT/
immobilized TA were comparable to WT/non-immobilized TA
(Fig. 3A,B). In contrast, no Ang-(1-7)-mediated effect was observed
in the immobilized TA of Mas KO mice, in which MHC levels
decreased by 57.3% and 58.9% in the absence and presence of Ang-
(1-7), respectively (Fig. 3C,D).
To further assess UPP participation, the mRNA levels of
the ubiquitin E3 ligases atrogin-1 and MuRF-1 were evaluated.
Fig. 1. Angiotensin-(1-7) inhibits the decreased isometric force of muscle
under disuse through the receptor Mas. Tibialis anterior (TA) from (A) wild-
type (WT) and (B) Mas knockout (KO) mice treated with vehicle or Ang-(1-7)
and unilaterally immobilized (Imm) for 14 days. Maximal isometric strengths
(mN/mm2) against stimulation frequencies (Hz) were evaluated. Values
represent the mean±s.d. of three independent experiments. In each
experiment, five to seven mice were used for each experimental condition.
*P<0.05 vs vehicle-treated/non-immobilized TA.
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Ang-(1-7) administration respectively prevented antrogin-1 and
MuRF-1 inductions by 2.73- and 2.49-fold in WT/immobilized
TA as compared to vehicle-treated WT/immobilized TA
(Fig. 3E,F). No inhibited atrogin-1 and MuRF-1 upregulation
was found in Ang-(1-7)-treated Mas KO/immobilized TA
(Fig. 3G,H).
These results indicate that Ang-(1-7) inhibits the lowered MHC
levels and increased atrogin-1 and MuRF-1 expressions that occur
during cast immobilization through a mechanism dependent on the
Mas receptor.
Ang-(1-7) activates the IGF-1/IGFR-1/Akt pathway in disuse
skeletal muscle atrophy
Our group previously showed that Ang-(1-7) abolishes Ang-II-
induced skeletal muscle atrophy through amechanism dependent on
Akt activation (Cisternas et al., 2015). However, the actions of Ang-
Fig. 2. Angiotensin-(1-7) prevents the decreased fiber diameter of muscle under disuse through the Mas receptor. The fiber diameter of tibialis anterior
(TA) cross-sections from (A,B) wild-type (WT) and (C,D) Mas knockout (KO) mice treated with the vehicle or Ang-(1-7) and unilaterally immobilized for 14 days
were compared. (A,C) Muscle cross-sections were stained with WGA to delimit muscle fiber sarcolemma. Scale bars: 150 µm. (B,D) Minimal Feret diameters
were determined in TA cross-sections from A and C. Fiber diameters were grouped from 0 to 100 µm. The values are expressed as the percentage of the total
quantified fibers, and the image counts are representative of three independent experiments. In each experiment, five to seven mice were used for each
experimental condition. Values correspond to the mean±s.d. The dotted line represents the median distribution of minimal Feret diameters observed in vehicle-
treated/non-immobilized TA. For better visualization of the changes, the upper panel of B and D compare the diameter of vehicle-treated/non-immobilized TA (No
Imm) and vehicle-treated/immobilized TA (Imm), whereas the lower panel shows the same comparison in the Ang-(1-7)-treated group. *P<0.05 vs vehicle-treated/
non-immobilized TA.
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(1-7) on downstream Akt targets in disuse muscle atrophy were
unknown. Therefore, Akt phosphorylation was first assessed by
western blot. In WT/non-immobilized TA, Ang-(1-7) pre-treatment
induced greater Akt phosphorylation as compared to vehicle-treated
WT/non-immobilized TA (Fig. 4A). Interestingly, decreased Akt
phosphorylation in vehicle-treated WT/immobilized TA was
prevented by Ang-(1-7), reaching rates higher than the basal
levels evidenced by vehicle-treated WT/non-immobilized TA
(Fig. 4A,B).
Next, the phosphorylation of FoxO3, a transcription factor and
downstream target of Akt, was evaluated. In the non-immobilized
TA of WT hind limb, Ang-(1-7) treatment resulted in higher FoxO3
phosphorylation than did vehicle treatment (Fig. 4A,B). Ang-(1-7)
administration also prevented decreased FoxO3 phosphorylation
in WT/immobilized TA as compared to the vehicle treatment
(Fig. 4A,B).
Then, the activation of p70S6K, another downstream target
of Akt, was assessed. p70S6K phosphorylation only slightly
Fig. 3. Angiotensin-(1-7) prevents the decreased myosin heavy chain levels and increased atrogin-1 and MuRF-1 expressions of muscle under
disuse through the Mas receptor. The hind limb of wild-type (WT) and Mas knockout (KO) mice in the presence or absence of Ang-(1-7) was unilaterally
immobilized (Imm) for 14 days. The tibialis anterior (TA) from immobilized (A)WTand (C) Mas KOmicewere isolated and homogenized to evaluate myosin heavy
chain (MHC) protein levels through western blot analysis. Tubulin levels were used as the loading control. Molecular mass markers are shown in kilodaltons.
(B,D) Quantitative analysis of the experiments from A and C, respectively. The levels of MHC normalized to tubulin are expressed relative to vehicle-treated/non-
immobilized TA and correspond to the mean±s.d. from three independent experiments. In each experiment, five to seven mice were used for each experimental
condition. *P<0.05 vs vehicle-treated/non-immobilized TA; #P<0.05 vs vehicle-treated/immobilized TA. Detection of atrogin-1 (E,G) and MuRF-1 (F,H) mRNA
levels through RT-qPCR using 18S as the reference gene. (E,F) WT mice; (G,H) Mas KO mice. Expressions are shown as the fold of induction relative to
vehicle-treated/non-immobilized TA and the values correspond to the mean±s.d. of three independent experiments. In each experiment, five to seven mice were
used for each experimental condition. *P<0.05 vs vehicle-treated/non-immobilized TA; #P<0.05 vs vehicle-treated/immobilized TA.
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decreased in vehicle-treated WT/immobilized TA as compared to
WT/non-immobilized TA (Fig. 4A). Similar levels of p70S6K
phosphorylation were found in Ang-(1-7)-treated WT/non-
immobilized and immobilized TA, which were elevated compared
to vehicle-treated WT/non-immobilized TA.
Regarding Ang-(1-7)-treated Mas KO/immobilized TA, Akt,
FoxO3 and p70S6K phosphorylation were dependent on the Mas
receptor. Thus, Ang-(1-7) was unable to revert the decreased
phosphorylation of these targets caused by disuse, whereas
phosphorylation levels in the TA of non-immobilized Mas KO
mice were similar between groups (Fig. 4C,D).
Finally, the effects of Ang-(1-7) on IGF-1 and IGFR-1
expression, as well as on IGFR-1 phosphorylation, were
determined. Vehicle-treated WT/immobilized TA showed
decreased IGF-1 expression (Fig. S5A), which was prevented in
Ang-(1-7)-treated WT/immobilized TA. In Mas KO/immobilized
TA, Ang-(1-7) did not prevent decreased IGF-1 gene expression
(Fig. S5B). In turn, IGFR-1 receptor expression was unchanged in
the TA for all conditions in WT and Mas KO mice (Fig. S5C,D).
Then, we evaluated the effect of Ang-(1-7) on IGFR-1
phosphorylation. The basal levels of IGFR-1 phosphorylation
decreased in vehicle-treated WT TA and Mas KO TA after 1 day
of immobilization (Fig. 5A,B), and this effect was still observed
after 14 days of immobilization (Fig. 5C). Also, at day 14, Ang-
(1-7) prevented decreased IGFR-1 phosphorylation in WT/
immobilized TA, but not in the Mas KO/immobilized TA
(Fig. 5C,D). Together, these results suggest that the receptor
Mas is involved in the recovery of Ang-(1-7)-induced IGF-1
expression and IGFR-1 phosphorylation at day 14 of
immobilization.
Primary culture myotubes were used to evaluate the correlation
between Ang-(1-7)-induced activation/phosphorylation of IGFR-1
and Akt. In response to Ang-(1-7) treatment, IGFR-1 was
phosphorylated by 24 h post-treatment, whereas Akt showed
biphasic kinetics of activation, with early (30 min) and late (24 h)
phosphorylation (Fig. S6A,B). To evaluate whether Ang-(1-7)-
induced Akt phosphorylation was dependent on IGFR-1
activation, primary myotube cultures were treated with
Fig. 4. Angiotensin-(1-7) activates the IGF-
1/Akt signalling pathway during muscle
disuse through the Mas receptor. The hind
limb of wild-type (WT) andMas knockout (KO)
mice in the presence or absence of Ang-(1-7)
were unilaterally immobilized for 14 days. The
tibialis anterior (TA) from (A) WT and (C) Mas
KO mice were isolated and homogenized to
evaluate the protein levels of phosphorylated
Akt, FoxO3 and p70S6K via western blot. The
total levels of Akt, FoxO3 and p70S6K were
used as the loading control. Molecular mass
markers are shown in kilodaltons.
(B,D) Quantitative analysis of the experiments
from A and C, respectively. The levels of
phospho-protein normalized to total protein
are expressed relative to the vehicle-treated/
non-immobilized TA and correspond to the
mean±s.d. from three independent
experiments. In each experiment, five to
seven mice were used for each experimental
condition. *P<0.05 vs vehicle-treated/non-
immobilized TA; #P<0.05 vs vehicle-treated/
immobilized TA.
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picropodophyllin (PPP), an inhibitor of IGFR-1 activation. Pre-
treatment with PPP did not change the Ang-(1-7)-dependent Akt
phosphorylation at 30 min (Fig. 5E-G), suggesting an effect
independent of IGFR-1 activation. However, PPP pre-treatment
decreased the Ang-(1-7)-induced Akt phosphorylation at 24 h
concomitant with the inhibition of IGFR-1 phosphorylation
(Fig. 5H-J).
These results indicate that Ang-(1-7), together with the Mas
receptor, can activate the IGF-1/IGFR-1/Akt pathway and
thereby promote IGF-1 expression, in addition to IGFR-1 and Akt
phosphorylation. These activities concomitantly inhibited the
activity of FoxO3 and activated the phosphorylation of p70S6K.
DISCUSSION
This is the first report on the anti-atrophic effects of Ang-(1-7) via
Mas in disuse skeletal muscle atrophy. Ang-(1-7) treatment
maintained muscle strength and prevented decreases in muscle
diameter and mass in the immobilized hind limb. Additionally,
Fig. 5. Angiotensin-(1-7) activates Akt by a mechanism dependent on IGF-1-receptor activation. Tibialis anterior (TA) from wild-type (WT) and Mas
knockout (KO) mice were treated with vehicle or Ang-(1-7) and unilaterally immobilized for 1 (A,B) or 14 (C,D) days. The muscles were homogenized and protein
levels of phosphorylated and total IGFR-1 were detected by western blot (A,C). Molecular mass markers are shown in kilodaltons. (B,D) Quantitative analysis of
the experiments from A and C, respectively. The levels of phospho-protein normalized to total protein are expressed relative to the vehicle-treated/non-
immobilized TA and correspond to the mean±s.d. from three independent experiments. In each experiment, five to seven mice were used for each
experimental condition. *P<0.05 vs vehicle-treated/non-immobilized TA; #P<0.05 vs vehicle-treated/immobilized TA. (E,H) Primary cultures of myotubes obtained
from hind limb of WT mice were treated for 1 h with picropodophyllin (PPP; 1 µM), an inhibitor of IGFR-1, prior to the incubation with Ang-(1-7) (10 nM) for 30 min
(E) or 24 h (H). Western blot for total and phosphorylated forms of IGFR-1 and Akt were performed. Molecular mass markers are shown in kilodaltons.
Quantification of phospho-IGFR-1 (F,I) and phospho-Akt (G,J) normalized to total protein are expressed relative to the vehicle-treated control group and
correspond to the mean±s.d. from two independent experiments in triplicate for each experimental condition. *P<0.05 vs vehicle-treated control; #P<0.05 vs
Ang-(1-7)-treated control.
446
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 441-449 doi:10.1242/dmm.023390
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Ang-(1-7), through Mas, prevented decreased MHC levels while
decreasing the expression of atrogin-1 and MuRF-1, two UPP
components typically upregulated by disuse. Moreover, the Ang-
(1-7)/Mas axis increased the expression of the IGF-1/IGFR-1/Akt
pathway, as demonstrated by increased IGF-1 expression; the
induction of Akt phosphorylation via IGFR-1; and the activation of
p70S6K and FoxO3, two downstream targets of Akt. These Ang-(1-
7)-related effects were not observed in Mas KO mice, indicating
Mas receptor participation in the anti-atrophic actions of Ang-(1-7).
RAS axis and disuse muscle atrophy
In the contexts of skeletal muscle physiopathology, the functions of
RASaremore thoroughly documented than those ofMas. In classical
RAS, Ang II is the main effector molecule, with a role in triggering
cachexia musclewasting (Cabello-Verrugio et al., 2012a, 2015). Our
group recently demonstrated that Ang-(1-7), themain peptide of non-
classical RAS, has an opposing role to Ang II in cachexia (Cisternas
et al., 2015; Meneses et al., 2015). In cases of disuse atrophy,
increased Ang II levels have not been reported. However, the
pharmacological inhibition of theAng II receptor, AT1,with losartan
decreases disuse skeletal muscle atrophy in older mice (Burks et al.,
2011). Interestingly, when AT1 is blocked by losartan, circulating
Ang-(1-7) levels increase (Schindler et al., 2007). This indicates that
Ang-(1-7) could be mediating the beneficial effects observed for
losartan use. Further experiments that evaluate the effects of losartan
inMas KOmice suffering disuse skeletal muscle atrophy would be a
relevant step towards elucidating this point.
Anti-atrophic effect of Ang-(1-7) is dependent on Mas in
disuse muscle atrophy
The present data clearly indicate the participation of the Mas
receptor in the anti-atrophic effects of Ang-(1-7). This is in
agreement with previous reports by our group that used the Mas
antagonist A779 (Cisternas et al., 2015; Meneses et al., 2015).
Although the participation of Mas in mediating the effects of Ang-
(1-7) is well documented, the intracellular pathways directly
downstream of the Mas receptor remain unclear. Mas is a G-
protein-coupled receptor, the effects of which are mediated by Gq or
Gi/o (Solinski et al., 2014). One of the important intracellular G-
protein adaptors is β-arrestin, which could be relevant in skeletal
muscle atrophy because it has been linked to MAPK and Akt
activation. Therefore, a relevant pending issue for further research is
to understand the molecular link between Mas and the Akt
signalling pathway during skeletal muscle atrophy.
The current study also indicates that Ang-(1-7) could have
therapeutic potential in combating disuse atrophy. Resistance
exercises that promote adaptive functional and structural
responses are widely applied in the treatment of disuse atrophy
(Nicastro et al., 2011). Notably, exercise training increases Ang-(1-
7) levels and Mas receptor expression in the muscles of rats
suffering chronic heart failure (Gomes-Santos et al., 2014). Chronic
Ang-(1-7) administration in spontaneously hypertensive rats
produces beneficial cardiovascular effects similar to those of
exercise training (Bertagnolli et al., 2014). In skeletal muscle,
exercise training causes a shift in RAS towards the Ang-(1-7)/Mas
axis, which might indicate that the beneficial effects of exercise can
be measured by increased Ang-(1-7) levels.
Roleof theAktpathway in theanti-atrophiceffectofAng-(1-7)
Our data strongly indicate that Akt is a key protein for determining
the effects of Ang-(1-7) on skeletal muscle. It is therefore important
that Ang-(1-7)-dependent Akt phosphorylation was found to be
mediated by the Mas receptor, as inferred through a lack of
phosphorylation dependent on Ang-(1-7) in Mas KO mice. The
observed Akt activation in the skeletal muscle of Ang-(1-7)-treated
mice is in line with previous reports (Cisternas et al., 2015; Munoz
et al., 2010). The central role of Akt in skeletal muscle atrophy is
supported by studies showing greater muscle atrophy in Akt1- and
Akt2-KO mice (Peng et al., 2003). Furthermore, the levels of
phosphorylated Akt markedly decrease during unloading-induced
muscle atrophy, and events downstream of Akt, such as p70S6K
phosphorylation and protein synthesis, also decrease (Hornberger
et al., 2001). In regards to this, our group previously showed that
Ang-(1-7) reduces Ang-II-mediated atrophic effects in skeletal
muscle by restoring muscle strength and mass (Cisternas et al.,
2015; Meneses et al., 2015) through a mechanism dependent on Akt
phosphorylation (Cisternas et al., 2015). According to the present
and previously reported results, Ang-(1-7) might not only activate
Akt but could also modulate the main pathway involved in protein
synthesis, thereby contributing to the prevention of disuse skeletal
muscle atrophy. Further studies are required to evaluate the effect of
Ang-(1-7) on protein synthesis.
In addition to favouring protein synthesis, Akt also inhibited
protein degradation through the phosphorylation of FoxO
transcription factors. When FoxO is phosphorylated, it is
maintained in the cytoplasm and prevents the upregulation of the
ubiquitin E3 ligases atrogin-1 and MuRF1. By preventing
ubiquitination, the subsequent proteasome-induced degradation of
myofibrillar proteins, such as MHC, is also impeded (Stitt et al.,
2004). During disuse, the IGF-1/Akt pathway is depressed (Childs
et al., 2003; Latres et al., 2005), blunting FoxO phosphorylation,
consequently leading to increased atrogin-1 and MuRF-1 levels that
finally undergo nuclear translation and induce the transcription of
the atrogin-1 andMuRF-1 genes (Sandri, 2008). This study was the
first to find Ang-(1-7) stimulating FoxO3A phosphorylation in both
basal and disuse conditions. This could indicate that the presence of
Ang-(1-7) inhibits the transcriptional activity of FoxO3, thus
decreasing the expressions of atrogin-1 and MuRF-1 and the
activation of UPP. In turn, this could explain the Ang-(1-7)-
mediated inhibition of decreasedMHC protein levels. Future studies
should consider evaluating the effects of Ang-(1-7) on other
pathways involved in protein degradation during muscle atrophy,
such as those dependent on calpains and/or autophagy.
Participationof IGF-1/IGFR-1pathwayontheeffectofAng-(1-7)
in disuse muscle atrophy
As mentioned, IGF-1/Akt pathway activity decreases in disuse
muscle atrophy (Childs et al., 2003; Latres et al., 2005). The
downregulation of IGF-1 signalling in skeletal muscle is related to
muscle wasting (Latres et al., 2005), and a transgenic expression of
IGF-1 in skeletal muscle has been linked to myofiber hypertrophy
(Coleman et al., 1995). In contrast, IGF-1 overexpression reverses
muscle wasting in several different models of muscle atrophy
(Schakman et al., 2005; Yoshida et al., 2010). Despite these studies,
the role of IGF-1 in disuse atrophy is controversial, with some
studies suggesting that IGF-1 overexpression does not impact
muscle atrophy attenuation (Criswell et al., 1998). The present study
found that Ang-(1-7) increased IGF-1 levels and IGFR-1 activation,
which could explain the increased Akt phosphorylation and
subsequent activation of downstream targets. Supporting these
results, a recent study reported that losartan attenuates disuse muscle
atrophy by activating the IGF-1/Akt pathway (Burks et al., 2011).
This study is the first to present evidence for the anti-atrophic
effects of Ang-(1-7) in disuse muscle atrophy together with the
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participation of the IGF-1/Akt signalling pathway. Preventing
muscle wasting is of major medical importance and is a crucial issue
in terms of healthcare costs. Thus, there is an ever-growing need to
find new rational therapeutic strategies for the prevention and/or
reversal of skeletal muscle atrophy. Such strategies could markedly
accelerate rehabilitation following injury or orthopaedic cast
immobilization, thereby reducing overall health care costs.
MATERIALS AND METHODS
Animals
Twelve-week-old male wild-type (WT) and Mas knockout (Mas KO)
(Walther et al., 1998) C57BL/6J mice were used. A lower hind limb was
unilaterally immobilized for different time periods using the 3M™
Scotchcast™ Soft Cast Casting Tape (Morales et al., 2015). The mice
were randomly separated into four different experimental groups, and three
independent experiments were performed. The experimental groups were
vehicle-treated WT (PBS), Ang-(1-7)-treated WT, vehicle-treated Mas KO
(PBS), and Ang-(1-7)-treated Mas KO. Mice were osmotically infused with
Ang-(1-7) (100 ng/kg body weight/min) 24 h before cast immobilization
through micropumps (ALZET®, Durect, USA), as previously described
(Acuna et al., 2014), and maintained during the immobilization period. At
the end of each experiment, the animals were euthanized with anaesthesia
overdose, and the tibialis anterior (TA) and gastrocnemius (GA) muscles
were dissected, removed, rapidly frozen, and stored at −80°C until
processing. All protocols were conducted in strict accordance to and with
the formal guidance and approval of the Animal Ethics Committee at the
Universidad Andrés Bello.
Muscle histology and muscle fiber determination and
quantification
Cryosections (7 µm) of the TA and GAwere stained with haematoxylin and
eosin (H&E) or Alexa-Fluor®-594-tagged WGA (Life Technologies™,
USA) according to standard procedures. Fiber sizes were determined by
WGA staining and the ImageJ software (NIH, USA), as previously
described (Cisternas et al., 2015; Meneses et al., 2015).
Contractile properties
After immobilization treatments, mice were given an anaesthetic overdose,
the TA and GA muscles were removed, and the contractile properties of the
muscles were measured as previously described. First, the maximum
isometric tetanic force was determined. Following this, the muscles were
removed from the bath, and the tendons and any non-muscle tissue were
trimmed, blotted once on filter paper, and weighed. Muscle mass and
optimum muscle length were used to calculate specific net force, or force
normalized to the total muscle fiber cross-sectional area (mN/mm2)
(Cabello-Verrugio et al., 2012b; Morales et al., 2011, 2013).
Primary cultures
Adult primary myoblasts were obtained from hind limb muscles of 10- to
20-week-old C57BL/6J mice. Briefly, dissected muscle was digested with
collagenase type I (Worthington, USA) for approximately 1 h. A single cell
suspension was obtained after filtering the samples through a 70 μm mesh
(Falcon). Cells were plated on collagen-coated dishes and cultured for the
indicated times in F12-C supplemented with 15% horse serum and 1 nM
FGF-2, at 37°C and 5% CO2 (Olguin and Olwin, 2004; Olguin et al., 2007).
Differentiation was induced by incubating the cultures in F12-C
supplemented with 2% horse serum. When required, the inhibitor
picropodophyllin (PPP) (Tocris Bioscience, USA; 1 µM) was added for
1 h before treatment with Ang-(1-7).
Quantitative real-time PCR
The mRNA expressions of mouse atrogin-1, MuRF-1, IGF-1, IGFR-1 and
the 18S housekeeping gene (TaqMan® Assays-on-Demand™; Applied
Biosystems®, USA) were quantified using the comparative ΔCt method
(2−ΔΔCT) (Schmittgen et al., 2000; Winer et al., 1999). The procedures for
RNA extraction and reverse transcription were performed as previously
described by our group (Morales et al., 2012).
Immunoblot analysis
Proteins from homogenized muscles were subjected to SDS-PAGE,
transferred onto polyvinylidene fluoride membranes (Millipore®, USA),
and probed with mouse anti-MHC (MF-20; Developmental Studies
Hybridoma Bank, University of Iowa, USA), mouse anti-tubulin (Santa
Cruz Biotechnology®, USA), rabbit anti-phospho Ser473 Akt, rabbit anti-
total Akt, rabbit anti-phospho Thr389 p70S6K, rabbit anti-total p70S6K,
rabbit anti-phospho Tyr1316 IGFR-1, rabbit anti-total IGFR-1 (Cell
Signaling Technology® Inc., USA), rabbit anti-phospho Ser253 FoxO3,
and rabbit anti-total FoxO3 (Bioss Antibodies™, USA). All
immunoreactions were visualized through enhanced chemiluminescence.
Statistical analysis
For statistical analysis, one or two-way analysis of variance (ANOVA) was
used with a post hoc Bonferroni multiple-comparison test (Prism®,
GraphPad Software, USA). Differences were considered statistically
significant at P<0.05.
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